When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.

about

Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?

P2860

Q54977220-779A96E8-2C20-43D4-B793-59FBC0C8B535

P2860

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.

Item

http://www.wikidata.org/entity/Q53703550

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.

@en

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.

@nl

type

Item

label

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.

@en

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.

@nl

prefLabel

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.

@en

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.

@nl

P1476

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.

@en

P2093

Pierre Laneuville

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987.

Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course.

Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia.

Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.

Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia.

P2888

s11864-018-0532-2

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S11864-018-0532-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2018-03-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29520446

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

mechanism of action

proto-oncogene proteins

neoplasm proteins

mutant proteins

chronic myeloid leukemia

Anzim

P932

5842492

http://www.w3.org/2001/XMLSchema#string

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.

about

P2860

P2860

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P433

P478

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P433

P478

P5008

P577

P698

P921

P932